Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis

Mitsuru Ishii; Masaharu Akao; Satoshi Yasuda; Koichi Kaikita; Junya Ako; Tetsuya Matoba; Masato Nakamura; Katsumi Miyauchi; Nobuhisa Hagiwara; Kazuo Kimura; Atsushi Hirayama; Kunihiko Matsui; Hisao Ogawa

doi:10.1161/JAHA.122.027107

Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis

Mitsuru Ishii, Masaharu Akao, Satoshi Yasuda, Koichi Kaikita, Junya Ako, Tetsuya Matoba, Masato Nakamura, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa

研究成果: Letter › 査読

本文言語	English
論文番号	e027107
ジャーナル	Journal of the American Heart Association
巻	11
号	21
DOI	https://doi.org/10.1161/JAHA.122.027107
出版ステータス	Published - 2022
外部発表	はい

ASJC Scopus subject areas

循環器および心血管医学

文献へのアクセス

10.1161/JAHA.122.027107

他のファイルとリンク

引用スタイル

Ishii, M., Akao, M., Yasuda, S., Kaikita, K., Ako, J., Matoba, T., Nakamura, M., Miyauchi, K., Hagiwara, N., Kimura, K., Hirayama, A., Matsui, K., & Ogawa, H. (2022). Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis. Journal of the American Heart Association, 11(21), [e027107]. https://doi.org/10.1161/JAHA.122.027107

Ishii, M, Akao, M, Yasuda, S, Kaikita, K, Ako, J, Matoba, T, Nakamura, M, Miyauchi, K, Hagiwara, N, Kimura, K, Hirayama, A, Matsui, K & Ogawa, H 2022, 'Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis', Journal of the American Heart Association, vol. 11, no. 21, e027107. https://doi.org/10.1161/JAHA.122.027107

@article{e429baaf0db644449b6f0ef797f518e7,

title = "Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis",

keywords = "antithrombotic therapy, atrial fibrillation, coronary stenting",

author = "Mitsuru Ishii and Masaharu Akao and Satoshi Yasuda and Koichi Kaikita and Junya Ako and Tetsuya Matoba and Masato Nakamura and Katsumi Miyauchi and Nobuhisa Hagiwara and Kazuo Kimura and Atsushi Hirayama and Kunihiko Matsui and Hisao Ogawa",

note = "Funding Information: The Japan Cardiovascular Research Foundation conducted the trial using funds provided by Bayer Yakuhin, Ltd. These funds were provided without restrictions or requirements. Mebix, Inc, for their contribution in the selection of the participating centers; in the supervision or monitoring of the centers; in collecting trial data; in storing trial data; in data analysis of the trial results, and in the provision of editorial assistance with the preparation of the manuscript under the guidance of authors, were financed by the Japan Cardiovascular Research Foundation based on funds received from Bayer Yakuhin, Ltd. This work was supported by the Japan Cardiovascular Research Foundation based on a contract with Bayer Yakuhin, Ltd., who had no role in the design of the trial, collection or analysis of the data, interpretation of the trial results, or writing of the manuscript.",

year = "2022",

doi = "10.1161/JAHA.122.027107",

language = "English",

volume = "11",

journal = "Journal of the American Heart Association",

issn = "2047-9980",

publisher = "Wiley-Blackwell",

number = "21",

}

TY - JOUR

T1 - Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk

T2 - The AFIRE Trial Subanalysis

AU - Ishii, Mitsuru

AU - Akao, Masaharu

AU - Yasuda, Satoshi

AU - Kaikita, Koichi

AU - Ako, Junya

AU - Matoba, Tetsuya

AU - Nakamura, Masato

AU - Miyauchi, Katsumi

AU - Hagiwara, Nobuhisa

AU - Kimura, Kazuo

AU - Hirayama, Atsushi

AU - Matsui, Kunihiko

AU - Ogawa, Hisao

N1 - Funding Information: The Japan Cardiovascular Research Foundation conducted the trial using funds provided by Bayer Yakuhin, Ltd. These funds were provided without restrictions or requirements. Mebix, Inc, for their contribution in the selection of the participating centers; in the supervision or monitoring of the centers; in collecting trial data; in storing trial data; in data analysis of the trial results, and in the provision of editorial assistance with the preparation of the manuscript under the guidance of authors, were financed by the Japan Cardiovascular Research Foundation based on funds received from Bayer Yakuhin, Ltd. This work was supported by the Japan Cardiovascular Research Foundation based on a contract with Bayer Yakuhin, Ltd., who had no role in the design of the trial, collection or analysis of the data, interpretation of the trial results, or writing of the manuscript.

PY - 2022

Y1 - 2022

KW - antithrombotic therapy

KW - atrial fibrillation

KW - coronary stenting

UR - http://www.scopus.com/inward/record.url?scp=85141003554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141003554&partnerID=8YFLogxK

U2 - 10.1161/JAHA.122.027107

DO - 10.1161/JAHA.122.027107

M3 - Letter

C2 - 36285792

AN - SCOPUS:85141003554

SN - 2047-9980

VL - 11

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

IS - 21

M1 - e027107

ER -